US-based biopharmaceutical firm Helix BioPharma has opened patient screening for the ninth dose level group in its ongoing Phase I/II trial of L-DOS47 in Poland (LDOS002).
The open-label Phase I/II clinical trial is designed to assess the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The opening of patient screening follows completion of the first treatment cycle in the three patients enrolled in the eighth dose level group, in which L-DOS47 therapy was well tolerated, as reviewed by the Trial Steering Committee.
Helix president and chief executive officer Robert Verhagen said: "With the continued dose escalation, now in the ninth dose level cohort for our Polish study, and the recent US Food and Drug Administration approval of the LDOS001 Phase I study, the company will have taken an important step in the development of L-DOS47."
L-DOS47 is the company’s first immunoconjugate-based drug candidate being developed based on a new DOS47 technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells.
L-DOS47 is currently being clinically assessed as a treatment for certain patients with non-small cell lung cancer (NSCLC).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to the company, patients to be enrolled in the ninth group will receive the next L-DOS47 dose level as planned in the trial protocol, which is 1.84mcg of L-DOS47 a kilogram of patient body weight.
Approved in the US, LDOS001 is an open-label Phase I dose escalation trial of L-DOS47, in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous NSCLC.
